局部应用贝伐单抗作为角膜新生血管辅助治疗的效果。 - Suppr

Suppr

超能文献

The effect of topical bevacizumab as an adjunctive therapy for corneal neovascularization.

作者信息

Asena Leyla, Akova Yonca A, Cetinkaya Altug, Kucukerdonmez Cem

出版信息

Acta Ophthalmol. 2013 May;91(3):e246-8. doi: 10.1111/j.1755-3768.2012.02540.x. Epub 2012 Sep 23.

DOI:10.1111/j.1755-3768.2012.02540.x

PMID:22998029

Abstract

摘要

相似文献

The effect of topical bevacizumab as an adjunctive therapy for corneal neovascularization.

Acta Ophthalmol. 2013 May;91(3):e246-8. doi: 10.1111/j.1755-3768.2012.02540.x. Epub 2012 Sep 23.

Bevacizumab for corneal neovascularization.

Ophthalmology. 2009 Mar;116(3):592-3; author reply 593-4. doi: 10.1016/j.ophtha.2008.10.011.

Combined use of subconjunctival and intracorneal bevacizumab injection for corneal neovascularization.

Cornea. 2011 Oct;30(10):1110-4. doi: 10.1097/ICO.0b013e31821379aa.

Angioregressive pretreatment of mature corneal blood vessels before keratoplasty: fine-needle vessel coagulation combined with anti-VEGFs.

Cornea. 2012 Aug;31(8):887-92. doi: 10.1097/ICO.0b013e31823f8f7a.

The effect of topical bevacizumab on corneal neovascularization.

Ophthalmology. 2008 Jun;115(6):e33-8. doi: 10.1016/j.ophtha.2008.02.013. Epub 2008 Apr 24.

Topical bevacizumab therapy for corneal neovascularization.

Arch Ophthalmol. 2007 Jun;125(6):834-6. doi: 10.1001/archopht.125.6.834.

Subconjunctival bevacizumab induces regression of corneal neovascularisation: a pilot randomised placebo-controlled double-masked trial.

Br J Ophthalmol. 2013 Jan;97(1):28-32. doi: 10.1136/bjophthalmol-2012-302137. Epub 2012 Oct 20.

Topical bevacizumab and ocular surface neovascularization in patients with stevens-johnson syndrome.

Cornea. 2008 Jan;27(1):70-3. doi: 10.1097/ICO.0b013e318158f6ad.

Topical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model.

Ophthalmic Res. 2012;48(3):118-23. doi: 10.1159/000337139. Epub 2012 Apr 24.

Subconjunctival bevacizumab for corneal neovascularization.

Cornea. 2008 Oct;27(9):992-5. doi: 10.1097/ICO.0b013e31817786ad.

引用本文的文献

Therapy outcomes of IL-17 and JAK inhibitors in rosacea: A systematic review.

J Biomed Res. 2024 Aug 21;39(3):317-318. doi: 10.7555/JBR.38.20240107.

Comparison of the Therapeutic Efficacies of Topical Rivoceranib and Topical Bevacizumab in a Murine Model of Corneal Neovascularization.

Medicina (Kaunas). 2019 Nov 7;55(11):729. doi: 10.3390/medicina55110729.

Functional Staging of Corneal Neovascularization Using Fluorescein and Indocyanine Green Angiography.

Transl Vis Sci Technol. 2018 Oct 1;7(5):15. doi: 10.1167/tvst.7.5.15. eCollection 2018 Sep.

Topical bevacizumab treatment in aniridia.

Int Ophthalmol. 2018 Aug;38(4):1741-1746. doi: 10.1007/s10792-017-0605-4. Epub 2017 Jun 15.

Clinical Findings, Follow-up and Treatment Results in Patients with Ocular Rosacea.

Turk J Ophthalmol. 2016 Jan;46(1):1-6. doi: 10.4274/tjo.48902. Epub 2016 Jan 5.

Topical Bevacizumab for the Treatment of Ocular Surface Squamous Neoplasia.

J Ocul Pharmacol Ther. 2015 Oct;31(8):487-90. doi: 10.1089/jop.2014.0158. Epub 2015 Jun 26.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验